WELCOME TO Million Health Pharmaceuticals


Bdenza 40mg containing anti-androgen agent like Enzalutamide, it expels an anti-tumor activity in different steps. Bdenza tablets are interfere in androgen receptor signaling pathway, which prohibiting androgen binding to androgen receptors leads to androgen receptor nuclear translocation inhibition and interact with DNA. The major metabolite of Bdenza is N-desmethyl Enzalutamide which is similar to Enzalutamide activity. The anti-tumor activity of Bdenza is exposed by depleting the multiplication and persuades cell lysis in prostate cancer cells.


The usual recommended dosage of Bdenza is 160mg, but available strength of Bdenza 40mg Four tablets of Bdenza 40mg should be taken at a time as a single dose. Bdenza tablet should be administered with or without food.

Dosing alteration: In ≥ grade 3 toxicity or extreme side effects: Postpone the dose of Bdenza for 1 week or as far as symptoms progress to ≤ grade 2, continue at the same or reduced to 120mg or 80mg. Concurrent use with strong CYP2C8 inhibitors:

In case of combination with strong CYP2C8 inhibitors, diminish the dose of Bdenza to 80mg as a single dose. Concurrent use with strong CYP3A4 inducers: In case of combination with strong CYP3A4 inducers, increasing the dose of Bdenza 160mg to 240mg as a single dose.


Brand : Bdenza
Ingredients : Enzalutamide
Strength : 40mg
Manufactured : BDR pharmaceuticals
Package : 28 Tablets


After an oral administration of Bdenza 40mg tablets (160mg of dose), undergoes ADME process and exhibits activity. The peak plasma concentration time of Bdenza occurs at 1 hour with the range of 0.5 to 3 hours). The steady state of Bdenza occurs in day 28. The volume of distribution occur after single dose of Bdenza is 110L Bdenza has highly bounds to the human plasma protein with the range of 97 to 98%.

The major metabolite of Enzalutamide is N-desmethyl Enzalutamide has 95% bound to human plasma protein. The most important isoenzymes responsible for the metabolism of Enzalutamide are CYP2C8 & CYP3A4. CYP2C8 is involved in the formation of an active metabolite N-desmethyl Enzalutamide. Bdenza is majorly excreted through liver metabolism, 71% of metabolite present in urine and 14% in feces. The terminal half life period of Bdenza 40mg tablet is occurs after a single dose at 5.8days and N-desmethyl Enzalutamide is taken 7.8 to 8.6 days.


Asthenia Peripheral edema Back pain, arthralgia Musculoskeletal pain Muscular weakness Musculoskeletal stiffness Diarrhea Hot flush Hypertension Headache Dizziness Spinal cord compression Caude equine syndrome Paresthesia Mental disorders Hypoesthesia Respiratory tract infections Insomnia Anxiety Hematuria Pollakiuria Non pathologic fractures Pruritus Dry skin Epistaxis


The major adverse effect during the therapy of Bdenza tablets are;

Seizure may produce during the treatment with Bdenza tablets, if seizure occurs the treatment should be discontinued until seizure resolved. To avoid this condition, patient should be counsel about the problems occurred during the therapy before starting the treatment. Seizure may leads to loss of consciousness.

Posterior reversible encephalopathy syndrome PRES
Patient who are all taking Bdenza tablets acquired PRES, is a neurological problem produce symptoms like headache, lethargy, confusion, loss of vision, other neurological problems related with hypertension. PRES diagnosed by MRI. If patient acquired with PRES, discontinue the Bdenza therapy



Bdenza tablets concomitant with strong CYP2C8 inhibitors like gemfibrozil which may increase the plasma concentration time curve of Enzalutamide, so avoid this concomitant if possible. If required condition, the dose of Bdenza is reduced to 80mg. Bdenza tablet combined with CYP3A4 inducers, causes depletion of AUC of Enzalutamide and its active metabolite. CYP3A4 inducers like rifampicin, anti-convulsants, st. Johns wort. This combination should be avoided, in unavoidable condition the dose of Bdenza is increased up to 240mg. Bdenza with st. Johns wort causes depletion of Enzalutamide exposure.

Bdenza with CYP3A4 strong inducer, CYP2C9 & CYP2C19 moderate inducers; CYP3A4 strong inducer: Midazolam CYP2C9: warfarin CYP2C19: Omeprazole The concurrent use of Bdenza with these drugs may cause depletion of plasma exposure of these drugs. Drugs metabolized by CYP3A4 such as cyclosporine, dihydroergotamine, fentanyl, pimozide, quinidine, sirolimus etc combined with Bdenza causes decreasing the exposure of these drugs.

Quick Contact

Prescription upload

Top Products


Millionpharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Millionpharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Millionpharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Millionpharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Millionpharma.com

At Millionpharma.com , a Caregiver can order prescription medicines on your behalf.


This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.